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Abstract The role of caspases in B lymphocyte cell death was
investigated by using two broad spectrum inhibitors of the
caspase family, Z-Asp-cmk and Z-VAD-fmk. They totally
prevented spontaneous and drug-induced apoptosis and inhibited
the CPP32/caspase-3-like activity exhibited by apoptotic cells.
However, the suppression of apoptosis was not associated with a
long-term increase of cell survival, but conversely, with a switch
from apoptotic death to the necrotic form. These results strongly
suggest that apoptosis and necrosis share common initiation
pathways, the final issue being determined by the presence of an
active caspase.
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1. Introduction
Apoptosis, considered the physiological form of cell demise,
as opposed to necrosis or accidental cell death, is an active
process with distinct morphological and biochemical features
[1^3]. Thus, apoptotic cells are characterized by condensed
and fragmented nuclei, whereas necrotic cells present loss of
plasma membrane integrity without apparent damage to nu-
clei. However, these two apparently opposite forms of cell
death can be elicited by the same stimuli, according to their
intensities [4,5], suggesting that initial common events could
be shared by apoptosis and necrosis.
Apoptosis requires tightly regulated death pathways, in-
cluding activation of cysteine proteases of the caspase family.
These are characterized by the cleavage of speci¢c substrates
after an aspartic residue, and considered essential in the ex-
ecution stage of the apoptotic process [6^10]. Caspase-3/
CPP32-like proteases appear to be important in apoptosis of
mammalian cells [11^14].
Peptide inhibitors, designed to mimic known sequences of
caspase substrates, have been shown to suppress apoptosis in
a number of cell culture systems, with the general assumption
that inhibition of apoptosis would lead to cell survival. How-
ever, the long-term e¡ect of caspase inhibition has rarely been
investigated and contradictory results have been reported on
whether the death process is completely prevented or only
delayed [15^17]. It is also unknown whether the death occur-
ring later is through necrosis or apoptosis.
The present study was undertaken to investigate the re-
quirement for caspase activity in spontaneous and in drug-
induced apoptosis in B lymphocytes. CPP32/caspase-3-like ac-
tivity was essential in both cases. Surprisingly, while peptide
caspase inhibitors totally inhibited apoptotic features, they did
not improve long-term cell survival because they only deviated
the apoptotic process to the necrotic form of cell death. The
data suggest that caspase activity is determinant in the choice
between apoptosis and necrosis.
2. Materials and methods
2.1. Materials
The caspase inhibitors Z-Asp-cmk and Z-VAD-fmk were purchased
from Bachem Biochimie (France). The caspase substrates YVAD-
pNA and DEVD-pNA were purchased from Alexis Biochemicals (Co-
ger, France). The culture medium used throughout was RPMI 1640
(Biomedia, France) supplemented with 25 mM HEPES, 2 mM L-glu-
tamine, standard antibiotics, 50 WM 2-mercaptoethanol and 8% heat-
inactivated fetal calf serum (Biomedia, France). Dibutyryl-cAMP
(dbcAMP), dexamethasone (DEX), 6-diamidino-2-phenylindole
(DAPI), £uorescein diacetate (FDA), ethidium bromide (EtBr), hy-
drogen peroxide (H2O2) and the kit for lactate dehydrogenase analysis
were purchased from Sigma (St. Louis, MO, USA).
2.2. B lymphocyte preparation and culture
Female C57BL/6 mice were purchased at 6^8 weeks of age (I¡a
Credo, France). Mature B lymphocytes were puri¢ed as previously
described [18]. Brie£y, splenocytes (3^4U106/ml in RPMI medium)
were treated with anti-T cell monoclonal antibodies (Tebu, France)
at 4‡C for 60 min followed by incubation with guinea pig complement
at 37‡C for 60 min (Tebu, France). Cells were layered on top of a
discontinuous Percoll gradient and cells at the 65^70% interface were
recovered. B cells, at 5U105 cells/ml, were cultured in 24-well plates
(Nunclon) in 6% CO2 at 37‡C. For cytometric analysis, cells were
¢xed in 70% ethanol and stored at 320‡C.
2.3. Assessment of cell viability and cell death
Cells (106 cells/ml) were washed with PBS and then double-stained
with FDA (1 Wg/ml) and EtBr (10 Wg/ml) for 5 min at 37‡C. FDA,
after being taken up by live cells, is cleaved by intracellular esterases,
yielding green £uorescent £uorescein retained in the cytoplasm. EtBr,
a non-speci¢c DNA intercalating agent, is excluded by the plasma
membrane of living cells and hence only dead cells exhibited or-
ange-red £uorescent nuclei [19]. Quantitative analysis of each popula-
tion was performed by counting more than 500 cells discriminated as
viable (green £uorescence and unstained normal nucleus), apoptotic
(red condensed or fragmented nucleus) and necrotic (red ‘apparently
normal’ or patchy nucleus). Cell death was also assessed by measuring
LDH release according to the manufacturer’s instructions. LDH leak-
age was expressed as follows: 100ULDH in supernatants/(cytoplas-
mic LDH+LDH in supernatants). The results are presented as the
mean of three experiments þ S.D.
2.4. Apoptosis determination by £ow cytometry
Fixed cells (106 cells/ml) were washed twice with HBSS and then
stained with DAPI (2.5 Wg/ml) at 37‡C for 30 min. DNA content was
quanti¢ed by £ow cytometric analysis performed on a PARTEC CA
II £ow cytometer (Chemunex France) equipped with a 100 W mercury
lamp (type HBO). Fluorescence at 455 nm was recorded as a function
of DNA content. Each histogram was generated until the analysis
reached at least 15 000 cells. The percentage of apoptosis was deter-
mined from the sub-G1 events.
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2.5. Analysis of DNA fragmentation in agarose gels
DNA from 5U105 B lymphocytes was processed as previously de-
scribed [20]. Brie£y, after cell lysis, DNA was extracted and precipi-
tated with 70% ethanol at 320‡C overnight. Electrophoresis was per-
formed in 1% agarose gel containing 1 Wg/ml EtBr. DNA was
visualized in UV light.
2.6. Determination of [3H]thymidine incorporation
B lymphocytes (105) were cultured in 96-well microtiter plates in a
0.2 ml ¢nal volume per well in the presence of various stimuli. Pro-
liferation was assessed on day 3 by pulsing cultures with 0.5 WCi of
tritiated thymidine ([3H]TdR, Amersham, Les Ulis, France) 6 h before
harvesting. [3H]TdR uptake was expressed as mean cpm for triplicate
cultures.
2.7. Caspase assay
After 8 h culture in the presence or absence of drugs, as indicated,
B lymphocytes (5U106) were washed and lysed in Triton X-100 bu¡er
(0.5% Triton X-100, 2 mM EDTA, 1 mM PMSF) for 20 min on ice.
Cell lysates were added with 0.5 ml of ICE bu¡er (100 mM HEPES-
KOH pH 7.5, 10% sucrose, 10 mM DTT and 0.1% CHAPS) contain-
ing 100 WM DEVD-pNA or YVAD-pNA caspase substrates, and then
incubated for 1 h and 10 h at 37‡C. Enzyme-catalyzed release of pNA
was monitored at 405 nm.
3. Results and discussion
3.1. Caspase inhibitors induce a shift from spontaneous
apoptosis to necrosis
In order to determine the role of caspases in B lymphocyte
apoptosis we tested the e¡ect of Z-Asp-cmk and Z-VAD-fmk,
two broad spectrum and irreversible inhibitors of the caspase
family. Consistent with previous reports [21], B lymphocytes
in vitro underwent a time-dependent cell death by apoptosis
(Fig. 1A). Z-Asp-cmk (50 WM) and Z-VAD-fmk (100 WM)
totally prevented the apoptotic process as assessed by mor-
phological observation (Fig. 1B), cytometric analysis and lad-
dering of DNA (Fig. 2A,B). However, the suppression of
apoptosis was not associated with a long-term increase of
cell viability, but conversely was linked to an induction of
necrosis, as determined by counting cells after staining with
FDA and EtBr (Fig. 1A and see Section 2.3). As can be seen
in Fig. 1, the two peptides appeared to act in a di¡erent way
since a threshold of more than 20 WM of Z-Asp-cmk was
required to prevent apoptosis and to deviate the form of
cell death, whereas Z-VAD-fmk, dose-dependently, inhibited
the onset of apoptosis with a concomitant shift to necrosis. In
addition, at their e¡ective dose, Z-Asp-cmk, but not Z-VAD-
fmk, led to a transitional increase of cell viability when com-
pared to controls, accompanied by a delay of about 8 h in the
switch to necrosis (Fig. 1A). Since long-term e¡ects of both
inhibitors were similar, we only present the results obtained
with Z-VAD-fmk which has a higher speci¢city for the cas-
pase family.
Cell death analysis, as evaluated by LDH leakage from
dying cells, con¢rmed that Z-VAD-fmk did not prevent cell
death since LDH release after 6 h and 24 h was not reduced
when compared to controls (Fig. 2C). Cell survival was also
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Fig. 1. Inhibition of apoptosis and induction of necrosis in B lymphocytes by caspase inhibitors. A: Time course of apoptosis: cells were incu-
bated in the absence or the presence of Z-Asp-cmk (50 WM) and Z-VAD-fmk (100 WM), and the percentage of viable, apoptotic and necrotic
cells was determined morphologically (see Section 2.3). B: Dose response of Z-Asp-cmk and Z-VAD-fmk measured after 16 h of culture.
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assessed by measuring cell growth. Z-VAD-fmk did not im-
prove thymidine uptake by B lymphocytes and greatly im-
paired LPS-induced B cell proliferation on days two and three
(Fig. 2D). This is in agreement with data showing that the
proliferation potential of growth factor-dependent cell lines
[17], of ¢broblasts [16] and of Ramos BL cells [22] could
not be restored by inhibiting apoptosis through caspase inhib-
ition. On the other hand, repression of staurosporine-induced
apoptosis and of Fas-mediated apoptosis has been reported to
be associated with maintenance of viability and proliferation
[15,23].
3.2. Drug-induced apoptosis is inhibited by Z-VAD-fmk and
shifted to necrosis
The switch from apoptosis to necrosis was also observed
when apoptosis was increased by drug treatment of B lym-
phocytes. Consistent with previous reports [24,25], an impor-
tant time-dependent increase of apoptosis was observed in B
cells cultured in the presence of DEX or dbcAMP (Fig. 3A).
The presence of Z-VAD-fmk inhibited apoptosis, as demon-
strated by electrophoresis of DNA (Fig. 3B). To further in-
vestigate whether the shift to necrosis was a consequence
of caspase inhibition and was not associated with an
intrinsic activity of the drug itself, the time of addition
of Z-VAD-fmk was delayed relative to that of drugs. Fig.
3C shows that pretreatment (34 h) with Z-VAD-fmk did
not in£uence the intensity of the switch between apoptosis
and necrosis observed when cells were cultured for 24 h
in the presence of Z-VAD-fmk and drugs added simulta-
neously at T0 (0). In contrast, when Z-VAD-fmk addition
was delayed for 4 h, 6 h or 8 h, the apoptotic process being
already triggered in some cells, those cells committed to apop-
tosis could no longer be deviated to the necrotic form of
cell death. The deviation to necrosis was thus progressively
lost.
The present data indicate that, in B lymphocytes, once the
signaling pathway leading to caspase activation has been ini-
tiated, its inhibition leads to necrosis. These results are in
apparent contradiction to the general assumption that inhib-
ition of caspase would rescue cells from death. For example,
Z-VAD-fmk appeared to increase cell survival in Ramos BL
cells [22], in B-CLL [26], and in myeloid leukemic cell lines
[27], supporting a di¡erence of the susceptibility to death be-
tween cell lines or transformed cells and normal primary cells.
This could be linked to higher levels of ATP expressed by the
latter, since recent ¢ndings have demonstrated the essential
role of appropriate energy supply in the execution phase of
apoptosis. Accordingly, ATP depletion could shift the death
mechanism to necrosis [28,29]. Recently, a switch from apop-
tosis to necrosis has been observed in thymocytes cultured in
the presence of inducers of permeability transition and cas-
pase inhibitors; it was suggested that alteration of mitochon-
drial functions could constitute a common event in both
forms of cell death, the choice being determined by a caspase
event [30]. The present ¢ndings argue for such a hypothesis
and clearly demonstrate that speci¢c inhibition of potentially
active caspase counteracts only the form of cell death but not
the death itself.
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Fig. 2. Prevention of apoptosis without improvement of cell viability by caspase inhibition. A: Cytogram showing the disappearance of the
sub-G1 apoptotic peak, to the left of the dotted line, in Z-VAD-fmk-treated cells. B: Agarose gel electrophoresis of total DNA from B lym-
phocytes cultured for 24 h in the absence or the presence of increasing doses of Z-VAD-fmk. Lane M: ladder DNA markers. C: Cell death as
measured by LDH leakage from dead cells; H2O2 (1 mM) was used as a positive control of necrosis. D: Cell growth as determined by thymi-
dine incorporation on days 2 and 3 by cells cultured in the absence or the presence of LPS with or without Z-VAD-fmk (100 WM); results are
expressed as the mean of three distinct experiments þ S.D.
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3.3. Caspase-3-like protease is activated during spontaneous
and drug-induced apoptosis
To characterize the type of caspase involved in B lympho-
cyte apoptosis, the presence of ICE/caspase-1-like or CPP32/
caspase-3-like activity in cytoplasmic extracts was investi-
gated, by measuring the cleavage of their respective substrates,
YVAD-pNA or DEVD-pNA. Apoptotic cells were totally de-
void of ICE/caspase-1-like activity (data not shown). In con-
trast, Fig. 4 shows that spontaneous as well as DEX- and
dbcAMP-induced apoptotic cells cleaved the CPP32/caspase-
3-like DEVD-pNA substrate. In every case, this activity was
abrogated by the two peptide inhibitors Z-Asp-cmk and Z-
VAD-fmk. CPP32/caspase-3 activation has been implicated in
the apoptosis of Ramos BL B cell line [22] and in that of B-
chronic lymphocytic leukemia cells [26]. The present study
demonstrates, for the ¢rst time, its implication in the apopto-
sis of normal primary B lymphocytes, supporting the impor-
tance of CPP32/caspase-3-like proteases in the B cell lineage.
In conclusion, although necrosis and apoptosis have long
been considered unrelated phenomena, recent reports suggest
that the two forms of death might not be so distinct as ini-
tially thought. However, the signaling pathway leading to the
choice between life and death or between the two forms of cell
death is still unknown. The present data suggest that the
commitment to apoptotic or to necrotic cell death is a com-
mon event that could involve caspase expression as well, the
¢nal decision being linked to the capacity of caspases to exert
their activity.
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Fig. 3. Time-dependent switch from apoptosis to necrosis. B lymphocytes were cultured in the presence or the absence of dexamethasone
(DEX, 5 nM) or dbcAMP (cAMP, 100 WM). A: Time course of apoptosis induction. B: Electrophoresis of DNA from B lymphocytes cultured
for 24 h in the absence or the presence of DEX with or without Z-Asp-cmk and Z-VAD-fmk, concentrations indicated as WM. C: Frequency
of viable, apoptotic or necrotic cells was assessed 24 h after culturing in the presence or the absence of DEX or cAMP, whereas Z-VAD-fmk
(100 WM) was added before (34 h), simultaneously (0), or after (4 h, 6 h, 8 h) the initiation of cultures.
Fig. 4. Caspase-3-like activity in apoptotic cells. B lymphocytes
were cultured for 8 h in the presence or the absence of drugs, with
or without caspase inhibitors. Hydrolysis of DEVD-pNA substrate
was measured after 10 h at 405 nm.
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